Disputas – master of science Joseph Diab

Avhandlingen er tilgjengelig her!
The doctoral thesis is available here!

På grunn av koronautbruddet er auditoriet stengt for publikum. Disputasen vil i stedet bli strømmet. Opptak av disputasen vil være tilgjengelig i en måned.
The auditorium will be closed to the public because of the corona outbreak. The defense will be streamed. A recording of the disputation will be available for one month.

Prøveforelesning over oppgitt emne starter kl. 10.15/ The trail lecture starts at 10.15
Tittel/Title:  “Proteomics in Inflammatory Bowel Disease - Integrated multi-omics to facilitate personalized medicine in IBD”

Prøveforelesningen strømmes her / The trail lecture will be streamed here

Disputasen starter kl. 12.15 / The defense starts at 12.15
Disputasen strømmes her / The defense will be streamed here
De som ønsker å opponere ex auditorio kan sende e-post til leder av disputasen (natasa.skalko-basnet@uit.no). Opponents ex auditorio should sign up to leader of defense by e-mail (natasa.skalko-basnet@uit.no).

Populærvitenskapelig sammendrag av avhandlingen/ Summary of the thesis:

Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disorder in the gastrointestinal tract affecting up to 0.5% of the population of the Western world. The two major forms of IBD, Ulcerative Colitis (UC) and Crohn’s Disease (CD), are characterized by a dysregulated immune response triggered by several genetic, microbial and environmental factors.

We preformed mass spectrometry-based metabolomic and lipidomic analysis on colon biopsies from UC patients to unravel the disease pathobiology and to identify markers for the disease outcome. We found that the alteration in lipid mediators correlates with the severity of UC. Moreover, we report potential prognostic and diagnostic markers for UC, such as very long chain ceramids and lipid mediators. Likewise, tryptophan metabolism is a key aspect of the impaired metabolism in active UC.

This work demonstrates the importance of metabolomics in IBD to identify key drivers of pathogenesis which prerequisite personalized treatment.

Veiledere/ Supervisors:

Hovedveileder/Main supervisor:
Førsteamanuensis Guro Forsdahl, Institutt for farmasi, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet

Biveiledere/supervisors:
Professor John Florholmen, institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet
Førsteamanuensis Terkel Hansen, Institutt for farmasi, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet
Professor Einar Jensen, Institutt for farmasi, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet

Bedømmelseskomité/Defensecomitee:

Professor Margrét Þorsteinsdóttir, Faculty of Pharmaceutical Sciences, University of Iceland - 1. opponent
Førsteamanuensis Henrik Munch Roager, Department of Nutrition, Exercise and Sports, University of Copenhagen – 2.opponent
Førsteamanuensis Beate Garcia, Institutt for farmasi, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet – leder av komité

Disputasleder/ Leader of defense:

Professor Natasa Skalko-Basnet, Institutt for farmasi, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet